Positive News SentimentPositive News Applied Therapeutics (APLT) News Today $2.42 +0.31 (+14.69%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$2.10▼$2.4550-Day Range$1.84▼$2.8352-Week Range$0.70▼$3.11Volume790,082 shsAverage Volume521,193 shsMarket Capitalization$186.90 millionP/E RatioN/ADividend YieldN/APrice Target$9.50 HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineApplied Therapeutics GAAP EPS of -$0.47 misses by $0.21msn.com - November 9 at 10:25 AMApplied Therapeutics: Q3 Earnings Insightsbenzinga.com - November 9 at 10:25 AMApplied Therapeutics Reports Third Quarter 2023 Financial Resultsfinance.yahoo.com - November 9 at 10:25 AMApplied Therapeutics Inc (APLT) Reports Q3 2023 Financial Results Amidst Upcoming Clinical ...finance.yahoo.com - November 9 at 10:25 AMApplied Therapeutics, Inc. (NASDAQ:APLT) is definitely on the radar of institutional investors who own 38% of the companyfinance.yahoo.com - November 5 at 9:28 AMMassive Insider Trade At Applied Therapeuticsbenzinga.com - November 3 at 12:46 PMApplied Therapeutics to Present at the UBS Biopharma Conference 2023finance.yahoo.com - November 2 at 10:03 AMApplied Therapeutics to Host Diabetic Cardiomyopathy Expert Forum with Key Opinion Leaders on Tuesday, November 7finance.yahoo.com - November 1 at 9:00 AMApplied Therapeutics Inc APLTmorningstar.com - November 1 at 12:14 AMApplied Therapeutics to Present Baseline Data from Phase 3 ARISE-HF Study Evaluating AT-001 at the 2023 EASD Annual Meetingfinance.yahoo.com - September 28 at 9:51 AMApplied Therapeutics Shares Rise 11% After Pre-NDA Meeting With FDAmarketwatch.com - September 6 at 12:47 PMApplied Therapeutics Announces Successful Pre-NDA Meeting with the FDA and Confirms Plans to Submit NDA for Govorestat (AT-007) for Treatment of Classic Galactosemia to FDA in Q4 2023finance.yahoo.com - September 6 at 12:47 PMApplied Therapeutics: Buy For Upcoming Pre-NDA Meeting (I Expect A Positive Outcome)msn.com - August 17 at 9:30 AMApplied Therapeutics GAAP EPS of -$0.37seekingalpha.com - August 11 at 7:06 PMApplied Therapeutics Reports Second Quarter 2023 Financial Resultsfinance.yahoo.com - August 10 at 8:06 AMApplied Therapeutics (NASDAQ: APLT)fool.com - August 8 at 11:53 PMApplied Therapeutics to Present Baseline Data on the Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at the 2023 Annual Meeting of the American Diabetes Associationfinance.yahoo.com - June 22 at 8:04 AMAPLT - Applied Therapeutics, Inc.finance.yahoo.com - June 17 at 7:29 PMApplied Therapeutics to Present Data on AT-007 (Govorestat) Treatment in SORD Deficiency at the 2023 Annual Meeting of the Peripheral Nerve Societyfinance.yahoo.com - June 15 at 10:20 AMApplied Therapeutics govorestat gets orphan drug tag in EU for muscle disordermsn.com - May 25 at 9:22 AMGovorestat (AT-007) Receives Orphan Medicinal Product Designation from the EMA for Treatment of SORD Deficiencyfinance.yahoo.com - May 25 at 9:22 AMApplied Therapeutics Reports First Quarter 2023 Financial Resultsfinance.yahoo.com - May 11 at 8:40 AM7 Hot Growth Stocks Poised to Triple in 2023markets.businessinsider.com - May 5 at 2:56 PMBaird Maintains Applied Therapeutics (APLT) Outperform Recommendationmsn.com - April 25 at 4:28 PMApplied Therapeutics' Investigational Drug Shows Clinical Benefit In Rare Metabolic Disorder, Chalks Out FDA Submission Plansmsn.com - April 24 at 12:50 PMApplied Therapeutics up 12% on $30M offeringmsn.com - April 24 at 12:50 PMApplied Therapeutics, Inc. Announces $30 Million Private Placement of Equityfinance.yahoo.com - April 24 at 7:50 AMApplied Therapeutics Announces Clinical Benefit of Govorestat (AT-007) in ACTION-Galactosemia Kids Trial; Company Plans to Meet with FDA Regarding Potential NDA Submissionfinance.yahoo.com - April 24 at 7:50 AMApplied Therapeutics Reports Fourth Quarter and Year-end 2022 Financial Resultsfinance.yahoo.com - March 23 at 9:32 AMQuite a few insiders invested in Applied Therapeutics, Inc. (NASDAQ:APLT) last year which is positive news for shareholdersfinance.yahoo.com - March 18 at 1:13 PMApplied Therapeutics to Present at the Cowen 43rd Annual Health Care Conferencefinance.yahoo.com - March 1 at 7:17 AMApplied Therapeutics Reveals Pivotal Study Data In Hereditary Neuropathyfinance.yahoo.com - February 24 at 4:49 AMApplied Therapeutics rises ~10% as AT-007 shows efficacy in phase 3 trial for muscle disordermsn.com - February 16 at 8:52 AMApplied Therapeutics Announces Positive Sorbitol Reduction Data From the Ongoing Phase 3 INSPIRE Trial in Sorbitol Dehydrogenase (SORD) Deficiencyfinance.yahoo.com - February 16 at 8:52 AMApplied Therapeutics to Present at the SVB Securities Global Biopharma Conferencefinance.yahoo.com - February 9 at 8:42 AMShort Interest in Applied Therapeutics, Inc. (NASDAQ:APLT) Increases By 70.9%marketbeat.com - January 27 at 5:52 AMApplied Therapeuticsforbes.com - January 21 at 1:24 AMWhy Applied Therapeutics Shares Are Seeing Blue Skiesmsn.com - January 4 at 1:46 PMApplied Therapeutics, Inc. (APLT)uk.finance.yahoo.com - January 4 at 12:12 AMApplied Therapeutics Reports Third Quarter 2022 Financial Resultsfinance.yahoo.com - November 9 at 10:37 AMApplied Therapeutics Announces Multiple Data Presentations at the American Heart Association Scientific Sessions November 5-7, 2022finance.yahoo.com - October 31 at 9:59 AMApplied Therapeutics Announces Full Enrollment in the Registrational Phase 3 ARISE-HF Trial of AT-001 in Diabetic Cardiomyopathyfinance.yahoo.com - October 25 at 12:06 PMInsiders who purchased Applied Therapeutics, Inc. (NASDAQ:APLT) earlier this year lose an additional US$86k as the stock sinks to US$0.62finance.yahoo.com - October 9 at 11:56 AMApplied Therapeutics Down 33% on Clinical Trial Updatemarketwatch.com - October 6 at 4:14 PMApplied Therapeutics' Lead Candidate Pediatric Study Failed To Reach Statistical Significancefinance.yahoo.com - October 6 at 4:14 PMApplied Therapeutics: AT-007 Trial Shows Positive Data Trend; Yet To Reach Statistical Significancemarkets.businessinsider.com - October 6 at 11:12 AMApplied Therapeutics Announces Positive Data Trend in AT-007 ACTION-Galactosemia Kids Pediatric Trial; Trial Will Continue to 18 Months in Blinded Formatfinance.yahoo.com - October 6 at 11:12 AMBears are Losing Control Over Applied Therapeutics Inc. (APLT), Here's Why It's a 'Buy' Nowfinance.yahoo.com - September 2 at 6:42 PMWe're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Ratenasdaq.com - August 16 at 10:55 PMRecap: Applied Therapeutics Q2 Earningsmsn.com - August 12 at 7:38 PM Get Applied Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APLT and its competitors with MarketBeat's FREE daily newsletter. Email Address APLT Media Mentions By Week APLT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. APLT News Sentiment▼1.890.75▲Average Medical News Sentiment APLT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. APLT Articles This Week▼10▲APLT Articles Average Week Get Applied Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APLT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Larimar Therapeutics News Greenwich LifeSciences News Seres Therapeutics News Gossamer Bio News Verrica Pharmaceuticals News Nuvectis Pharma News Aldeyra Therapeutics News Aquestive Therapeutics News Allakos News Verastem News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat Originals This page (NASDAQ:APLT) was last updated on 12/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Applied Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.